Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQ001 (Itolizumab) in Moderate-to-Severe Uncontrolled Asthma
NCT04007198Phase 1Completed
- Sponsor
- Biocon
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing EQ001 with EQ001 Placebo (2 arms). Primary endpoint: Number of Treatment Emergent Adverse Events at Day 85. Started Jun 2019; status: completed.
02
Drugs
itolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04007198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007198.